A Randomized Controlled Trial on Women's Substance Abuse Treatment
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Substance Use Disorders
- Sponsor
- VA Office of Research and Development
- Enrollment
- 66
- Locations
- 2
- Primary Endpoint
- Addiction Severity Index Alcohol Composite
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to examine the efficacy of a gender-focused addiction treatment model (A Woman's Path to Recovery) versus a non-gender focused addiction treatment model (12-Step Facilitation) in a sample of women Veterans with substance use disorder.
Detailed Description
Substance use disorder (SUD) is problem among women military Veterans, especially younger ones. The goal of this study was to examine the efficacy a gender-focused model of SUD treatment (A Woman's Path to Recovery, WPR) compared to an evidence-based active comparator that is not gender-specific (12-Step Facilitation, 12SF), in a sample of for women Veterans. The investigators randomized 66 women Veterans, ages 18-65, who were diagnosed with current SUD and used substances in the last 90 days. The treatment phase was 12 weekly individual therapy sessions and all participants could also obtain treatment-as-usual (any other treatments they chose to attend). Assessments were conducted at baseline, end of treatment and 3-month follow up. Sample size was based on power analysis (an effect of .80 at a .05 level of significance). The primary outcome variable was substance use, with various secondary outcomes also studied (e.g., psychosocial functioning, psychiatric symptoms, coping skills, 12-step attendance). Urinalysis / breathalyzer (biological measures) were also included to validate substance use self-report. The investigators hypothesized that participants in the experimental condition (WPR) would have more positive outcomes on both primary and secondary variables compared to those in the comparison condition (12SF). The investigators also hypothesized that WPR patients would increase coping skills more and 12SF would increase 12-step attendance more, relative to the other condition.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Female Veteran
- •18-65 years of age
- •Meet DSM-IV criteria for current SUD with "current" defined as meeting SUD criteria per the DSM-IV and having used a substance within the 90 days prior to intake (to be able to accurately evaluate changes in their substance use from baseline)
- •Plan to stay in the Boston area for the next 6 months
- •Have a mailing address and live close enough to come to the hospital once weekly for treatment and/or assessment
- •Able to complete the Statement of Informed Consent
- •Willing to participate in all assessments and breathalyzer/urine testing
- •Willing to provide a release of information such that study staff can contact her other providers as needed regarding any concerns during her participation
- •Able to obtain medical clearance
- •Willing to allow us to contact family and/or friends if participant loses contact with us
Exclusion Criteria
- •Any acute medical condition that would interfere with the participant's ability to participate in treatment, or would be of such severity as to affect the individual's psychological functioning (e.g., cancer)
- •Current bipolar I disorder, schizophrenia or other psychotic disorders or mental retardation or organic mental disorder (determined by screening interview)
- •Any clinical sign that the client is not sufficiently stable to participate in the treatment, such as client's treatment provider indicating that participation in the treatment would be contraindicated
- •Dangerousness that would present a threat to other staff or other clients (e.g., history of recent assault)
- •Client is mandated to treatment
- •Psychopharmacologic treatment that is planned to change or likely to change substantively over the 3-month active treatment phase (with "substantive" defined as any addition of a new medication or major shift in dosage)
Outcomes
Primary Outcomes
Addiction Severity Index Alcohol Composite
Time Frame: Baseline, end of treatment (month 3), 3-month post-treatment follow-up
Alcohol use and associated problems as measured by blinded-interviewer rated composite score. Six questions comprise the alcohol composite, of which 4 are answered from 0-30 (number of days in past month) and 2 are subjective Likert ratings 0 (not at all) to 4 (extremely), with higher scores on all items indicating worse pathology. Composite scores are computed and range from 0 (worst outcome) to 1 (best outcome). Breathalyzer was also obtained to verify self-report and was coded as positive (worst pathology, means patient was intoxicated) or negative (not pathological; patient was not intoxicated).
Addiction Severity Index Drug Composite
Time Frame: Baseline, end of treatment (3 months), and 3-month post-treatment followup
Drug use and associated problems as measured by blinded-interviewer rated composite score. Urinalysis/breathalyzer is also obtained to verify self-report.Drug use and associated problems as measured by blinded-interviewer rated composite score. Eleven questions comprise the drug composite, of which 9 are answered from 0-30 (number of days in past month) and 2 are subjective Likert ratings 0 (not at all) to 4 (extremely), with higher scores on all items indicating worse pathology. Composite scores are computed and range from 0 (worst outcome) to 1 (best outcome). Urinanalysis was also obtained to verify self-report and was coded as positive (worst pathology, means patient was intoxicated) or negative (not pathological; patient was not intoxicated).
Brief Addiction Monitor
Time Frame: Baseline, end of treatment (month 3), 3-month post-treatment follow-up
Assesses number of days in the past 30 days that person used substances including alcohol and drugs
Secondary Outcomes
- Addiction Severity Index Medical Composite Score(Baseline, end of treatment (month 3), 3-month post-treatment follow-up)
- Addiction Severity Index Employment Composite(Baseline, end of treatment (month 3), 3-month post-treatment follow-up)
- Addiction Severity Index Family/Social Composite(Baseline, end of treatment (month 3), 3-month post-treatment follow-up)
- BASIS-24 Psychosocial Functioning(Baseline, end of treatment (month 3), 3-month post-treatment follow-up)
- Coping Skills Measure(Baseline, end of treatment, 3-month post-treatment follow-up)
- Addiction Severity Index Psychiatric Composite(Baseline, end of treatment (month 3), 3-month post-treatment follow-up)
- Global Severity Index of the Brief Symptom Inventory(Baseline, end of treatment (month 3), 3-month post-treatment follow-up)
- Alcoholics Anonymous (AA) Intention Measure(Baseline, end of treatment (month 3), 3-month post-treatment follow-up)